Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Ovarian Neoplasms 2Osteosarcoma 2Neuroblastoma 2Lymphoma, Mantle-Cell 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neutropenia 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Multiple Myeloma 1Microphthalmia, Isolated, with Coloboma 5 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

Temozolomide 6Cyclophosphamide 5Filgrastim 3Automobiles 3sargramostim 2fludarabine 2Thalidomide 2Magnetic Resonance Spectroscopy 2Etoposide 2Carmustine 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2veliparib 1trifluridine tipiracil drug combination 1trametinib 1thymoglobulin 1temsirolimus 1sonidegib 1ribociclib 1reolysin 1pegfilgrastim 1ibrutinib 1fludarabine phosphate 1entinostat 1carboxyamido-triazole 1azurin (50-77) 1aldesleukin 1Zoledronic Acid 1Vincristine 1Verteporfin 1Valproic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neuroectodermal Tumors, Primitive × pegfilgrastim × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡